The Children’s Cancer Research Fund (CCRF) Survivorship Award supports research aimed at improving the quality and length of life for childhood, adolescent, and young adult (AYA) cancer survivors, with a specific focus on preventing, minimizing, and addressing the late effects of cancer therapies. Proposals may target drug or modality development to mitigate late effects, as well as translational projects converting basic findings into survivorship interventions — whether during active therapy or after. Observational studies are accepted but are lower priority unless they specifically describe late effects among children receiving novel agents. The award follows a two-step LOI and full application process, with peer review by scientific experts and the CCRF Research Advisory Committee.
Eligibility Criteria:
- Applicants must be eligible to serve as a Principal Investigator at their sponsoring institution (any career stage)
- Institution must be a US-based non-profit academic, medical, or research institution; applicants need not be US citizens
- Awarded PIs must commit at least 10% of research effort annually to the funded project
- Only one LOI per PI per calendar year accepted across all CCRF mechanisms
- A PI may hold only one active CCRF grant at a time
- Co-investigators and collaborators permitted; award administered by a single institution
- New applications, pilot study follow-ons, and previously reviewed-but-unfunded NIH R03/R21 applications (scored 20th percentile or better) are eligible; CCRF does not fund research using human embryonic stem cells or fetal tissue
- Members of the CCRF Research Advisory Committee are not eligible to apply
Funding Details:
- Up to $125,000 per year (including up to 10% indirect costs of direct costs) for a maximum of 24 months ($250,000 total)
- Allowable costs: salaries (subject to NIH salary cap), fringe, supplies, sub-contracts, publication costs, equipment, and travel (up to $2,000/year for conference travel)
- Up to 25% budget carryover permitted between years; one no-cost extension (max 12 months) possible with approval
- Progress reports due at 12, 18, and 24 months post-award
Deadline:
- LOI deadline: April 24, 2026 by 8:00 PM Eastern (submit via Proposal Central)
- Invitation to submit full proposal: July 1, 2026
- Full proposal deadline: August 10, 2026 by 8:00 PM Eastern
- Award notification: January 2027; project start no later than June 30, 2027
Where to Go for Further Information:
- Apply via Proposal Central
- Programmatic and eligibility questions: grants@childrenscancer.org
- Technical support (Proposal Central): pcsupport@altum.com